Shashikant Apte

1.7k total citations
31 papers, 198 citations indexed

About

Shashikant Apte is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Shashikant Apte has authored 31 papers receiving a total of 198 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hematology, 9 papers in Genetics and 5 papers in Oncology. Recurrent topics in Shashikant Apte's work include Hemophilia Treatment and Research (18 papers), Platelet Disorders and Treatments (9 papers) and Blood Coagulation and Thrombosis Mechanisms (7 papers). Shashikant Apte is often cited by papers focused on Hemophilia Treatment and Research (18 papers), Platelet Disorders and Treatments (9 papers) and Blood Coagulation and Thrombosis Mechanisms (7 papers). Shashikant Apte collaborates with scholars based in India, United States and Denmark. Shashikant Apte's co-authors include Cédric Hermans, Elena Santagostino, Alok Srivastava, Cecil Ross, Maria Elisa Mancuso, Aditi Joshi, Anand Pathak, Bipin Kulkarni, Chandrakala Shanmukhaiah and Mehran Karimi and has published in prestigious journals such as Blood, Journal of Thrombosis and Haemostasis and Haemophilia.

In The Last Decade

Shashikant Apte

27 papers receiving 191 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shashikant Apte India	9	146	43	32	23	22	31	198
Hoa Tran Norway	9	183 1.3×	46 1.1×	29 0.9×	14 0.6×	26 1.2×	23	241
M. El Khorassani Morocco	7	43 0.3×	23 0.5×	61 1.9×	24 1.0×	13 0.6×	25	132
Floor CJI Moenen Netherlands	4	83 0.6×	25 0.6×	17 0.5×	5 0.2×	5 0.2×	11	120
Dawn Goodyear Canada	5	71 0.5×	15 0.3×	46 1.4×	14 0.6×	16 0.7×	13	127
Emöke Deschmann Sweden	6	96 0.7×	22 0.5×	63 2.0×	4 0.2×	12 0.5×	9	172
Sébastien Bertil France	6	20 0.1×	20 0.5×	49 1.5×	6 0.3×	8 0.4×	11	119
Marek Bronisz Poland	5	135 0.9×	47 1.1×	22 0.7×	5 0.2×	2 0.1×	7	212
Genadi Iosava United States	6	248 1.7×	75 1.7×	14 0.4×	14 0.6×	1 0.0×	9	297
Jayanthi Alamelu United Kingdom	10	241 1.7×	47 1.1×	17 0.5×	3 0.1×	3 0.1×	17	272
Cathy G. Rosenfield United States	6	317 2.2×	96 2.2×	30 0.9×	2 0.1×	9 0.4×	11	381

Countries citing papers authored by Shashikant Apte

Since Specialization

Citations

This map shows the geographic impact of Shashikant Apte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shashikant Apte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shashikant Apte more than expected).

Fields of papers citing papers by Shashikant Apte

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shashikant Apte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shashikant Apte. The network helps show where Shashikant Apte may publish in the future.

Co-authorship network of co-authors of Shashikant Apte

This figure shows the co-authorship network connecting the top 25 collaborators of Shashikant Apte. A scholar is included among the top collaborators of Shashikant Apte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shashikant Apte. Shashikant Apte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Angchaisuksiri, Pantep, Sylvia von Mackensen, Shashikant Apte, et al.. (2025). Concizumab prophylaxis in people with hemophilia A or B without inhibitors: patient-reported outcome results from the phase 3 explorer8 study. Research and Practice in Thrombosis and Haemostasis. 9(2). 102705–102705.

Chowdary, Pratima, Pantep Angchaisuksiri, Shashikant Apte, et al.. (2024). Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. The Lancet Haematology. 11(12). e891–e904. 7 indexed citations

Windyga, Jerzy, Shashikant Apte, Melissa Frei‐Jones, et al.. (2024). Disease and treatment burden of patients with haemophilia entering the explorer6 non‐interventional study. European Journal Of Haematology. 113(5). 631–640. 2 indexed citations

Shapiro, Amy D., Shashikant Apte, Ana Boban, et al.. (2024). Annualized Bleeding Rates in Patients with Hemophilia a or B and Inhibitors with and without Target Joints at Baseline: Results from the Concizumab Phase 3 Explorer7 Study. Blood. 144(Supplement 1). 715–715.

Chowdary, Pratima, Pantep Angchaisuksiri, Shashikant Apte, et al.. (2023). OC 59.1 Concizumab Prophylaxis in Patients with Haemophilia A or B without Inhibitors: Efficacy and Safety Results from the Primary Analysis of the Phase 3 Explorer8 Study. Research and Practice in Thrombosis and Haemostasis. 7. 100444–100444. 2 indexed citations

Shanmukhaiah, Chandrakala, Farah Jijina, Bipin Kulkarni, et al.. (2022). Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature. Haemophilia. 28(2). 286–291. 16 indexed citations

Rangarajan, Savita, M. Joseph John, Shashikant Apte, et al.. (2022). Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Hemophilia A in India. Indian Journal of Hematology and Blood Transfusion. 39(4). 624–629.

Rangarajan, Savita, M. Joseph John, Shashikant Apte, et al.. (2022). Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India. Indian Journal of Hematology and Blood Transfusion. 39(4). 630–634.

Shanmukhaiah, Chandrakala, Neeraj Sidharthan, Pankaj Malhotra, et al.. (2022). Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia. Indian Journal of Hematology and Blood Transfusion. 39(3). 435–441. 1 indexed citations

10.

Lee, Stephanie J., Franco Locatelli, Francis Ayuk, et al.. (2021). Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT). Blood. 138(Supplement 1). 3909–3909. 1 indexed citations

11.

Görlinger, Klaus, Sukesh C. Nair, Yatin Mehta, et al.. (2021). Patient blood management in India - Review of current practices and feasibility of applying appropriate standard of care guidelines. A position paper by an interdisciplinary expert group. Journal of Anaesthesiology Clinical Pharmacology. 37(1). 3–13. 8 indexed citations

12.

John, M. Joseph, Prantar Chakrabarti, Shashikant Apte, et al.. (2020). Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results. Research and Practice in Thrombosis and Haemostasis. 4(8). 1324–1330. 2 indexed citations

13.

Apte, Shashikant, et al.. (2019). Correlation of Day 8 Steroid Response with Bone Marrow Status Measured on Days 14 and 35, in Patients with Acute Lymphoblastic Leukemia Being Treated with BFM Protocol. Indian Journal of Hematology and Blood Transfusion. 35(4). 635–639. 2 indexed citations

14.

Apte, Shashikant, Vijay Ramanan, M. Joseph John, et al.. (2018). Safety and Efficacy of Intravenous Immunoglobulin (Flebogamma ^® 10% DIF) in Patients with Immune Thrombocytopenic Purpura. Immunotherapy. 11(2). 81–89. 4 indexed citations

15.

Apte, Shashikant, et al.. (2018). Bilateral, Simultaneous Total Knee Replacement (TKR) Surgery for Hemophilia a with Eloctate (Extended Half Life Product)—A Feasible and Cost Effective Approach. Blood. 132(Supplement 1). 4684–4684. 4 indexed citations

16.

Abraham, Aby, Shashikant Apte, Anu Korula, et al.. (2017). Meaningful Reduction of Annual Bleeding Rate with Lower Dose Prophylaxis in Minimally Treated Children with Hemophilia in India. Blood. 130. 1079–1079. 3 indexed citations

17.

Ross, Cecil, Savita Rangarajan, Mehran Karimi, et al.. (2017). Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency. Journal of Thrombosis and Haemostasis. 16(2). 253–261. 32 indexed citations

18.

Kovaleva, Lidia, et al.. (2016). Safety and Efficacy of a 10% Intravenous Immunoglobulin Preparation in Patients with Immune Thrombocytopenic Purpura: Results of Two International, Multicenter Studies. Immunotherapy. 8(12). 1371–1381. 9 indexed citations

19.

Jain, Jyoti, et al.. (2014). A STUDY OF CORRELATION BETWEEN THE ECHOCARDIOGRAPHIC CHANGES WITH THE DURATION AND SEVERITY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Journal of Evolution of Medical and Dental Sciences. 3(8). 1997–2002. 2 indexed citations

20.

Powell, Jerry S., Shashikant Apte, Hérvè Chambost, et al.. (2013). Long-lasting recombinant factor FIX Fc fusion (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. Journal of Thrombosis and Haemostasis. 11. 358–358. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact